Regional therapy

Hepatocellular Carcinoma

Volumn , Issue , 2008, Pages 661-694

  Lau, W Y ^a   Lai, Eric C H ^b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882692118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1142/9789812770059_0030     Document Type: Chapter

References (147)

1. Lau WY (2000). Primary hepatocellular carcinoma. In: Blumgart LH, Fong Y (eds.), Surgery of the Liver and Biliary Tract, Vol. 2, WB Saunders, London, England, pp. 1423-50.
2. Lau WY (2002). Management of hepatocellular carcinoma. JR Coll Surg Edinb 47:389-99.
3. Lau WY, Yu SC, Lai EC, Leung TW (2006). Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg 202:155-68.
4. Lau WY (2000). Radiotherapy with emphasis on radioembolization for liver tumors. In: Blumgart LH, Fong Y (eds.), Surgery of the Liver and Biliary Tract, Vol. II, WB Saunders, London, England, pp. 1545-64.
5. Lau WY, Leung TW, Yu SC, Ho SK (2003). Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future. Ann Surg 237:171-9.
6. Leung TWT (1999). Non-surgical management. In: Leong ASY, LiewCT, Lau JWY, Johnson PJ (eds.), Hepatocellular Carcinoma, Arnold, London, England, pp. 173-92.
7. Lai EC, Lau WY (2005). The continuing challenge of hepatic cancer in Asia. Surgeon 3:210-5.
8. Lai EC, Choi TK, Tong SW, et al. (1986). Treatment of unresectable hepatocellular carcinoma: results of a randomized controlled trial. WorldJ Surg 10:501-9.
9. Plengvanit U, Chearanai O, Sindhvananda K, et al. (1972). Collateral arterial blood supply of the liver after hepatic artery ligation: angiographic study of twenty patients. Ann Surg 175:105-10.
10. Lai EC, Lau WY (2006). Spontaneous rupture of hepatocellular carcinoma: a systematic review. Arch Surg 141:191-8.
11. Bruix J, Llovet JM, Castells A, et al. (1998). Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578-83.
12. Llovet JM, Real MI, Montana X, et al.; Barcelona Liver Cancer Group (2002). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-9.
13. Civalleri D (1992). Methods to enhance the efficacy of regional chemotherapeutic treatment of liver malignancies. In: Civalleri D (ed.), An Update on Regional Treatment of Liver Cancer, Wells Medical Press, London, England, pp. 17-34.
14. Shildt R, Baker L, Stuckey W (1984). Hepatic artery infusion (HAI) with 5FDUR, adriamycin (A) and streptozotocin (St) in unresectable hepatoma. A Southwest Oncology Group Study. Proc Am Soc Clin Oncol 3:150.
15. Carr BI, Orons P, Zajko A, et al. (1994). Prolonged survival with chemotherapy alone for hepatocellular carcinoma (HCC) with intraarterial chemotherapy. Proc Am Soc Clin Oncol 13:A606.
16. Patt YZ, Charnsangavej C, Yoffe B, et al. (1994). Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 12:1204-11.
17. Marelli L, Stigliano R, Triantos C, et al. (2007). Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25.
18. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF (2002). Chemoemboliza-tion of hepatocellular carcinoma. J Vasc Interv Radiol 13:S211-21.
19. Kawai S, Tani M, Okamura J, et al. (1997). Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 24(Suppl 6):S6-38-S6-45.
20. Watanabe S, Nishioka M, Ohta Y, et al. (1994). Prospective and randomized controlled study ofchemoembolization therapy in patients with advanced hepatocellular carcinoma. Cooperative Study Group for Liver Cancer Treatment in Shikoku area. Cancer Chemother Pharmacol 33 (Suppl):S93-6.
21. Kamada K, Nakanishi T, Kitamoto M, et al. (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison ofcisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12:847-54.
22. Ono Y, Yoshimasu T, Ashikaga R, et al. (2000). Long-term results of lipiodol- transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23:564-8.
23. Geschwind JF, Ramsey DE, van der Wal BC, et al. (2003). Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26:111-7.
24. Jaeger HJ, Mehring UM, Castaneda F, et al. (1996). Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Car-diovasc Intervent Radiol 19:388-96.
25. Yamashita Y, Torashima M, Oguni T, et al. (1993). Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation. Abdom Imaging 18:352-6.
26. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire (1995). A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-61.
27. Pelletier G, Roche A, Ink O, et al. (1990). A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11:181-4.
28. Pelletier G, Ducreux M, Gay F, et al. (1998). Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. JHepatol 29:129-34.
29. Stuart K, Stokes K, Jenkins R, et al. (1993). Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 72:3202-9.
30. Ernst O, Sergent G, Mizrahi D, et al. (1999). Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. AJRAm J Roentgenol 172:59-64.
31. Matsui O, Kadoya M, Yoshikawa J, et al. (1994). Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 33(Suppl):S84-8.
32. Nishimine K, Uchida H, Matsuo N, et al. (1994). Segmental transarterial chemoembolization with lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 33(Suppl):S60-8.
33. Child CG, Turcotte JG (1964). Surgery and portal hypertension. In: Dunply JE (ed.), The Liver and Portal Hypertension, WB Saunders, Philadelphia, PA, pp. 50-2.
34. Pugh RN, Murray-Lyon IM, Dawson JL, et al. (1973). Transection of the oesophagus for bleeding oesophageal varices. Br JSurg 60:646-9.
35. Okuda K, Ohtsuki T, Obata H, et al. (1985). Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer56:918-28.
36. The Cancer of the Liver Italian Program (CLIP) investigators (1998). A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 28:751-5.
37. Ueno S, Tanabe G, Sako K, et al. (2001). Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 34:529-34.
38. Farinati F, Rinaldi M, Gianni S, Naccarato R (2000). How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 89:2266-73.
39. Llovet JM, Bru C, Bruix J (1999). Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-38.
40. Leung TW, Tang AM, Zee B, et al. (2002). Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94:1760-9.
41. Mondazzi L, Bottelli R, Brambilla G, et al. (1994). Transarterial oily chemoem-bolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 19:1115-23.
42. Hatanaka Y, Yamashita Y, Takahashi M, et al. (1995). Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 195:747-52.
43. Savastano S, Miotto D, Casarrubea G, et al. (1999). Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child’s grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol28:334-40.
44. Llado L, Virgili J, Figueras J, et al. (2000). A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 88:50-7.
45. O’Suilleabhain CB, Poon RT, Yong JL, et al. (2003). Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90:325-31.
46. Takayasu K, Arii S, Ikai I, et al.; Liver Cancer Study Group of Japan (2006). Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-9.
47. Lopez RR Jr, Pan SH, Hoffman AL, et al. (2002). Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs. focal hepatocellular carcinoma. Arch Surg 137:653-7.
48. Kim HK, Chung YH, Song BC, et al. (2001). Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423-7.
49. Pentecost MJ, Daniels JR, Teitelbaum GP, Stanley P (1993). Hepatic chemoembolization: safety with portal vein thrombosis. J Vasc Interv Radiol 4:347-51.
50. Fan J, Wu ZQ, Tang ZY, et al. (2001). Multimodality treatment in hepatocellular carcinoma patients with tumor thrombi in portal vein. World J Gastroenterol7:28-32.
51. Tazawa J, Maeda M, Sakai Y, et al. (2001). Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 16:660-5.
52. Gates J, Hartnell GG, Stuart KE, Clouse ME (1999). Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 19:399-414.
53. Kim W, Clark TW, Baum RA, Soulen MC (2001). Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965-8.
54. Trevisani F, De Notariis S, Rossi C, Bernardi M (2001). Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 32:383-9.
55. Bismuth H, Morino M, Sherlock D, et al. (1992). Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 163:387-94.
56. Stefanini GF, Amorati P, Biselli M, et al. (1995). Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75:2427-34.
57. Vetter D, Wenger JJ, Bergier JM, et al. (1991). Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 13:427-33.
58. Ohnishi K, Tanabe Y, Ryu M, et al. (1987). Prognosis of hepatocellular carcinoma smaller than 5 cm in relation to treatment: study of 100 patients. Hepatology 7:1285-90.
59. Bronowicki JP, Vetter D, Dumas F, et al. (1994). Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer 74:16-24.
60. Sangro B, Herraiz M, Martinez-Gonzalez MA, et al. (1998). Prognosis of hepatocellular carcinoma in relation to treatment: a multivariate analysis of 178 patients from a single European institution. Surgery 124:575-83.
61. Rose AT, Rose DM, Pinson CW, et al. (1998). Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg 64:1128-34.
62. Aoyama K, Tsukishiro T, Okada K, et al. (1992). Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol 31(Suppl):S55-9.
63. Yamashita Y, Takahashi M, Koga Y, et al. (1991). Prognostic factors in the treatment ofhepatocellular carcinoma with transcatheter arterial embolization and arterial infusion. Cancer 67:385-91.
64. Biselli M, Andreone P, Gramenzi A, et al. (2005). Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol 3:918-25.
65. Liem MS, Poon RT, Lo CM, et al. (2005). Outcome of transarterial chemoem-bolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 11:4465-71.
66. Kamada K, Nakanishi T, Kitamoto M, et al. (2001). Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12:847-54.
67. Jansen MC, van Hillegersberg R, Chamuleau RA, et al. (2005). Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur JSurg Oncol 31:331-47.
68. Lo CM, Ngan H, Tso WK, et al. (2002). Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-71.
69. Llovet JM, Bruix J (2003). Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429-42.
70. Chok KS, Ng KK, Poon RT, et al. (2006). Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 141:1231-6.
71. Fan J, Tang ZY, Yu YQ, et al. (1998). Improved survival with resection after transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Dig Surg 15:674-8.
72. Majno PE, Adam R, Bismuth H, et al. (1997). Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688-701.
73. Harada T, Matsuo K, Inoue T, et al. (1996). Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 224:4-9.
74. Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatic malignancy - a strategy to increase resectability. Ann Surg Oncol (in press).
75. Lau WY, Ho SK, Yu SC, et al. (2004). Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg 240:299-305.
76. Nagasue N, Galizia G, Kohno H, et al. (1989). Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma: a retrospective comparison of 138 liver resections. Surgery 106:81-6.
77. Adachi E, Matsumata T, Nishizaki T, et al. (1993). Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis. Cancer 72:3593-8.
78. Uchida M, Kohno H, Kubota H, et al. (1996). Role of preoperative transcatheter arterial oily chemoembolization for resectable hepatocellular carcinoma. World J Surg 20:326-31.
79. Luo YQ, Wang Y, Chen H, Wu MC (2002). Influence of preoperative transcatheter arterial chemoembolization on liver resection in patients with resectable hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 1:523-6.
80. Sasaki A, Iwashita Y, Shibata K, et al. (2006). Preoperative transcatheter arterial chemoembolization reduces long-term survival rate after hepatic resection for resectable hepatocellular carcinoma. Eur J Surg Oncol 32:773-9.
81. Wu CC, Ho YZ, Ho WL, et al. (1995). Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82:122-6.
82. Harada T, Matsuo K, Inoue T, et al. (1996). Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 224:4-9.
83. Majno PE, Adam R, Bismuth H, et al. (1997). Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 226:688-701.
84. Paye F, Jagot P Vilgrain V, et al. (1998). Preoperative chemoembolization of hepatocellular carcinoma: a comparative study. Arch Surg 133:767-72.
85. Di Carlo V, Ferrari G, Castoldi R, et al. (1998). Pre-operative chemoembolization of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology45:1950-4.
86. Gerunda GE, Neri D, Merenda R, et al. (2000). Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl 6:619-26.
87. Zhang Z, Liu Q, He J, et al. (2000). The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma. Cancer 89:2606-12.
88. Sugo H, Futagawa S, Beppu T, et al. (2003). Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg27:1295-9.
89. Wu CC, Ho YZ, Ho WL, et al. (1995). Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 82:122-6.
90. Yamasaki S, Hasegawa H, Kinoshita H, et al. (1996). A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87:206-11.
91. Chan ES, Chow PK, Tai B, et al. (2000). Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2:CD001199.
92. Schwartz JD, Schwartz M, Mandeli J, Sung M (2002). Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3:593-603.
93. Nonami T, Isshiki K, Katoh H, et al. (1991).The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas. Ann Surg213:222-6.
94. Takenaka K, Yoshida K, Nishizaki T, et al. (1995). Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence ofhepatocellular carcinoma. Am J Surg 169:400-4.
95. Izumi R, Shimizu K, Iyobe T, et al. (1994). Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 20:295-301.
96. Li JQ, Zhang YQ, Zhang WZ, et al. (1995). Randomized study of chemoem-bolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 121:364-6.
97. Lai EC, Lo CM, Fan ST, et al. (1998). Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 133:183-8.
98. Venook AP, Ferrell LD, Roberts JP et al. (1995). Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. Liver Transpl Surg 1:242-8.
99. Harnois DM, Steers J, Andrews JC, et al. (1999). Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 5:192-9.
100. Graziadei IW, Sandmueller H, Waldenberger P et al. (2003). Chemoemboliza-tion followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9:557-63.
101. Oldhafer KJ, Chavan A, Fruhauf NR, et al. (1998). Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 29:953-9.
102. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. (2005). Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 11:767-75.
103. Perez Saborido B, Meneu JC, Moreno E, et al. (2005). Is transarterial chemoem-bolization necessary before liver transplantation for hepatocellular carcinoma?Am J Surg 190:383-7.
104. Nagao T, Inoue S, Yoshimi F, et al. (1990). Postoperative recurrence of hepatocellular carcinoma. Ann Surg 211:28-33.
105. Takayasu K, Wakao F, Moriyama N, et al. (1992). Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors. Hepatology 16:906-11.
106. Okazaki M, Yamasaki S, Ono H, et al. (1993). Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepato-gastroenterology 40:320-3.
107. Poon RT, Fan ST, Lo CM, et al. (1999). Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long term results of treatment and prognostic factors. Ann Surg 229:216-22.
108. Tanaka K, Okazaki H, Nakamura S, et al. (1991). Hepatocellular carcinoma: treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 179:713-7.
109. Marelli L, Stigliano R, Triantos C, et al. (2006). Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 32:594-606.
110. Tanaka K, Nakamura S, Numata K, et al. (1992). Hepatocellular carcinoma: treatment with percutaneous ethanol injection and transcatheter arterial embolization. Radiology 185:457-60.
111. Hasuike Y, Okamura J, Furukawa J, et al. (1992). Efficacy of combination treatment (TAE with adriamycin and ethanol) for hepatocellular carcinoma. Cancer Chemother Pharmacol 31(Suppl):S30-4.
112. Kato T, Saito Y, Niwa M, et al. (1994). Combination therapy of transcatheter chemoembolization and percutaneous ethanol injection therapy for unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol33(Suppl):S115-8.
113. Allgaier HP, Deibert P, Olschewski M, et al. (1998). Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection: a single center analysis including 132 patients. Int J Cancer 79:601-5.
114. Bartolozzi C, Lencioni R, Caramella D, et al. (1995). Treatment oflarge HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology197:812-8.
115. Becker G, Soezgen T, Olschewski M, et al. (2005). Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11:6104-9.
116. Koda M, Murawaki Y, Mitsuda A, et al. (2001). Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 92:1516-24.
117. Veltri A, Moretto P, Doriguzzi A, et al. (2006). Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). EurRadiol 16:661-9.
118. Yamakado K, Nakatsuka A, Akeboshi M, et al. (2004). Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival. Oncol Rep 11:105-9.
119. Yoo HS, Lee JT, Kim KW, et al. (1991). Nodular hepatocellular carcinoma. Treatment with subsegmental intraarterial injection of iodine 131-labeled iodized oil. Cancer 68:1878-84.
120. Yumoto Y, Jinno K, Inatsuki S, et al. (1992). Treatment of hepatocellular carcinoma by transcatheter hepatic arterial injection of radioactive iodized oil solution. Cancer Chemother Pharmacol 31(Suppl):S128-36.
121. Ho S, Lau WY, Leung TW, Johnson PJ (1998). Internal radiation therapy for patients with primary or metastatic hepatic cancer: a review. Cancer 83:1894-907.
122. Leung WT, Lau WY, Ho S, et al. (1994). Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. JNuclMed 35:1313-8.
123. Raoul JL, Guyader D, Bretagne JF, et al. (1994). Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 35:1782-7.
124. Raoul JL, Guyader D, Bretagne JF, et al. (1997). Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 26:1156-61.
125. 131iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 76:2202-10.
126. 131 I-lipiodol treatment for hepatocellular carcinoma: a pilot study. Cancer Biother Radiopharm 16:333-8.
127. 131I-labelled lipiodol. Br J Surg 90:1379-83.
128. Lau WY, Leung TW, Ho SK, et al. (1999). Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 353:797-801.
129. Partensky C, Sassolas G, Henry L, et al. (2000). Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 135:1298-300.
130. Boucher E, Corbinais S, Rolland Y, et al. (2003). Adjuvant intra-arterial injection ofiodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 38:1237-41.
131. 188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. JNuclMed 46:60-6.
132. 188Re-HDD/lipiodol for treatment of hepatocellular carcinoma: a feasibility study in patients with advanced cirrhosis. J Nucl Med 46:1326-32.
133. Murthy R, Nunez R, Szklaruk J, et al. (2005). Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl):S41-55.
134. m macroaggregated albumin. Br J Radiol 70:823-8.
135. Ho S, Lau WY, Leung TW, et al. (1997). Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 24:293-8.
136. Ho S, Lau WY, Leung TW, et al. (1996). Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumors. Eur J Nucl Med23:947-52.
137. 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 33:919-24.
138. Goin JE, Salem R, Carr BI, et al. (2005). Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 16:205-13.
139. Houle S, Yip TK, Shepherd FA, et al. (1989). Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 172:857-60.
140. Shepherd FA, Rotstein LE, Houle S, et al. (1992). A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 70:2250-4.
141. Geschwind JF, Salem R, Carr BI, et al. (2004). Yttrium-90 microspheres for the treatment ofhepatocellular carcinoma. Gastroenterology 127(Suppl):S194-205.
142. Liu MD, Uaje MB, Al-Ghazi MS, et al. (2004). Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. Am Surg 70:947-53.
143. 90yttrium glass microspheres (TheraSphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10(Suppl):S107-10.
144. 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 16:1627-39.
145. Lau WY, Leung WT, Ho S, et al. (1994). Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 70:994-9.
146. 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40:583-92.
147. Lau WY, Ho S, Leung WT, et al. (2001). What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres?Hepatogastroenterology 48:338-40.